FiercePharma's Carly Helfand and FierceBiotech's Damian Garde discuss the week's biggest news in biopharma, including the ongoing squabble between Teva and Mylan, the debate over a new class of cholesterol treatments, and the regulatory saga of a long-delayed female libido drug.
Download the episode on iTunes or Stitcher, or listen below--and be sure to subscribe. Let us know what you think by dropping a line to [email protected].